Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 6/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484084 | 0.91 | AGER (0.50) | AGERSCN9AFPR2NPC1LMNA | |
| SCHEMBL1283023 | 0.80 | AGER (0.45) | AGERSCN4ASCN9ACXCR3MAPK14 | |
| SCHEMBL1283790 | 0.78 | AGER (0.57) | AGERSCN4ASCN9AFPR2 | |
| SCHEMBL1283929 | 0.73 | AGER (0.42) | AGERSCN4ASCN9ACXCR3 | |
| SCHEMBL1283199 | 0.73 | SCN9A (0.40) | AGERSCN4ASCN9AFPR2 | |
| SCHEMBL1283498 | 0.71 | AGER (0.55) | AGERNPC1LMNAMAPK1RAB9A | |
| SCHEMBL1283344 | 0.71 | AGER (0.55) | AGERNPC1LMNAMAPK1RAB9A | |
| SCHEMBL1283677 | 0.71 | AGER (0.57) | AGERNPC1LMNAMAPK1RAB9A | |
| SCHEMBL6895313 | 0.71 | AGER (0.51) | AGERSCN9ANPC1LMNAMAPK1 | |
| SCHEMBL1283540 | 0.70 | AGER (0.38) | AGERSCN9ANPC1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | AGER 1/4885SCN4A 3475/4885SCN9A 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.